A. Abbara, Syndrome de Down, p.2017, 2017.

J. Alamercy, Suivi de la personne porteuse de trisomie 21 tout au long de sa vie, 2007.

S. E. Antonarakis and C. J. Epstein, The challenge of Down syndrome, Trends Mol Med, vol.12, issue.10, p.16935027, 2006.

S. E. Antonarakis, Down syndrome and the complexity of genome dosage imbalance, Nat Rev Genet, vol.18, issue.3, p.28029161, 2017.

B. H. Araujo, L. B. Torres, and L. M. Guilhoto, Cerebal overinhibition could be the basis for the high prevalence of epilepsy in persons with Down syndrome, Epilepsy Behav, vol.53, p.26558714, 2015.

A. Arumugam, Down syndrome-A narrative review with a focus on anatomical features, Clin. Anat, vol.29, p.26599319, 2016.

W. Ayed, L. Gouas, F. Penault-llorca, A. Amouri, A. Tchirkov et al., Trisomy 21 et cancers, Morphologie, vol.96, p.23141635, 2012.

A. Moreira, L. M. Damasceno, E. Santo, and L. , Marriage and reproduction in a woman with Down syndrome, Rev Med Int Sindr Down, vol.17, issue.3, pp.39-42, 2013.

R. A. Baum, P. L. Nash, J. E. Foster, M. Spader, K. Ratliff-schaub et al., Primary care of children and adolescents with down syndrome: an update, Curr Probl Pediatr Adolesc Health Care, vol.38, issue.8, p.18722332, 2008.

W. Becker, U. Soppa, and F. J. Tejedor, DYRK1A: a potential drug target for multiple Down syndrome neuropathologies, CNS Neurol Disord Drug Targets, vol.13, issue.1, p.24152332, 2014.

E. Blaise, Contribution à l'étude chimique et pharmacochimique de dérivés mono-bi-et tricycliques de pyridazines, 2014.

A. Bruwier and C. F. Chantrain, Hematological disorders and leukemia in children with Down syndrome, Eur J Pediatr, vol.171, issue.9, p.22113227, 2012.

D. A. Butterfield, Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications, Antioxid Redox Signal, vol.17, issue.11, p.22115501, 2012.

A. M. Cárdenas, A. O. Ardiles, N. Barraza, X. Baéz-matus, and P. Caviedes, Role of tau protein in neuronal damage in Alzheimer's disease and Down syndrome, Arch Med Res, vol.43, issue.8, p.23142525, 2012.

A. Chaanine, C. Hugonenq, G. Lena, and J. Mancini, Les complications neurologiques liées à la trisomie 21, Arch Pediatr, vol.15, issue.4, p.18329863, 2008.

C. P. Chen, Pathophysiology of increased fetal nuchal translucency thickness, Taiwan J Obstet Gynecol, vol.49, issue.2, p.20708516, 2010.

X. Y. Choong, J. L. Tosh, L. J. Pulford, and E. M. Fisher, Dissecting Alzheimer disease in Down syndrome using mouse models, Front Behav Neurosci, vol.9, p.26528151, 2015.

, Information destinée aux femmes enceintes sur la possibilité de recourir, à leur demande, au dépistage prénatal de la trisomie 21, Collège National des Gynécologues et Obstétriciens Français (CNGOF), p.2017, 2014.

F. Coppedè, The complex relationship between folate/homocysteine metabolism and risk of Down syndrome, Mutat Res, vol.682, issue.1, 2009.

F. Coppedè, The genetics of folate metabolism and maternal risk of birth of a child with Down syndrome and associated congenital heart defects, Front Genet, vol.6, p.26161087, 2015.

F. Coppedè, Risk factors for Down syndrome, Arch Toxicol, p.27600794, 2016.

A. C. Costa, On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome, Dev Neurosci, vol.33, issue.5, p.21893967, 2011.

A. C. Costa and J. J. Scott-mckean, Prospects for Improving Brain Function in Individuals with Down Syndrome, CNS Drugs, vol.27, issue.9, p.23821040, 2013.

N. Cramer and Z. Galdzicki, From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome, Neural Plast, vol.101542, p.22848844, 2012.

D. Das, C. Phillips, W. Hsieh, K. Sumanth, V. Dang et al., Neurotransmitter-based strategies for the treatment of cognitive dysfunction in Down syndrome, Prog Neuropsychopharmacol Biol Psychiatry, vol.54, p.24842803, 2014.

A. D. Dekker, P. P. De-deyn, and M. G. Rots, Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome, Neurosci Biobehav Rev, vol.45, p.24858130, 2014.

J. M. Delabar, R. Aflalo-rattenbac, and N. Créau, Developmental defects in trisomy 21 and mouse models, ScientificWorldJournal, vol.6, p.17205199, 2006.

J. M. Delabar, Syndrome de Down-Nouvelles perspectives the?rapeutiques ?, Med Sci (Paris), vol.26, issue.4, p.20412741, 2010.

J. D. Delhanty, Inherited aneuploidy: germline mosaicism, Cytogenet Genome Res, vol.133, issue.24, p.21487228, 2011.

S. I. Deutsch, J. A. Burket, M. R. Urbano, and A. D. Benson, The ?7 nicotinic acetylcholine receptor: A mediator of pathogenesis and therapeutic target in autism spectrum disorders and Down syndrome, Biochem Pharmacol, vol.97, issue.4, p.26074265, 2015.

M. Dierssen, C. Fillat, L. Crnic, M. Arbonés, J. Flórez et al., Murine models for Down syndrome, Physiol Behav, vol.73, issue.5, p.11566219, 2001.

M. Dierssen, J. Ortiz-abalia, G. Arqué, M. M. De-lagrán, and C. Fillat, Pitfalls And Hopes in Down Syndrome Therapeutic Approaches: In the Search for Evidence-Based Treatments, Behav Genet, vol.36, issue.3, p.16520905, 2006.

M. Dierssen and R. De-la-torre, Down Syndrome: From Understanding the Neurobiology to Therapy, Prog Brain Res, vol.197, 2012.

R. Diogo, C. M. Smith, and J. M. Ziermann, Human Evolution, Morphological Variations and Defects, and Medicine, Evolutionary Developmental Pathology and Anthropology: A New Field Linking Development, Comparative Anatomy, vol.244, p.26293597, 2015.

L. Eckmann, De?pistage non invasif de la Trisomie 21: entre chime?re et re?alite?. Mémoire SagesFemmes, 2014.

S. Egozcue, Human male infertility: chromosome anomalies, meiotic disorders, abnormal spermatozoa and recurrent abortion, Hum Reprod Update, vol.6, issue.1, p.10711834, 2000.

T. S. Elton, H. Selemon, S. M. Elton, and N. L. Parinandi, Regulation of the MIR155 host gene in physiological and pathological processes, Gene, vol.532, issue.1, p.23246696, 2013.

E. Engidawork and G. Lubec, Molecular changes in fetal Down syndrome brain, J Neurochem, vol.84, issue.5, p.12603815, 2003.

P. M. Ferraro, G. C. Curhan, G. Gambaro, and E. N. Taylor, Total, Dietary, and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones, Am J Kidney Dis, vol.67, issue.3, p.26463139, 2016.

. Fondation-jérôme-lejeune, , p.2017

K. G. Fonseka and D. K. Griffin, Is there a paternal age effect for aneuploidy?, Cytogenet Genome Res, vol.133, issue.2-4, p.21212646, 2011.

A. M. Fortress, E. D. Hamlett, E. M. Vazey, G. Aston-jones, W. A. Cass et al., Designer Receptors Enhance Memory in a Mouse Model of Down Syndrome, J Neurosci, vol.35, issue.4, p.4308587, 2015.

Z. Galdzicki, R. Siarey, R. Pearce, J. Stoll, and S. I. Rapoport, On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models, Brain Res Brain Res Rev, vol.35, issue.2, p.11336779, 2001.

K. Gardiner, Memory and learning-using mouse to model neurobiological and behavioural aspects of Down syndrome and assess pharmacotherapeutics. Down Syndrome Research and Practice (Online), 2008.

K. Gardiner, Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations, Drug Des Devel Ther, vol.9, p.25552901, 2015.

S. Gotti, E. Caricati, and G. Panzica, Alterations of brain circuits in Down syndrome murine models, J Chem Neuroanat, vol.42, issue.4, p.21946025, 2011.

T. F. Haydar and R. H. Reeves, Trisomy 21 and early brain development, Trends Neurosci, vol.35, issue.2, p.22169531, 2011.

M. Herbert, D. Kalleas, D. Cooney, M. Lamb, and L. Lister, Meiosis and maternal aging: insights from aneuploid oocytes and trisomy births, Cold Spring Harb Perspect Biol, vol.7, issue.4, 2015.

Y. Hibaoui and A. Feki, Concise Review: Methods and Cell Types Used to Generate Down Syndrome Induced Pluripotent Stem Cells, J Clin Med, vol.4, issue.4, p.26239351, 2015.

M. A. Hultén, S. Patel, J. Jonasson, and E. Iwarsson, On the origin of the maternal age effect in trisomy 21 Down syndrome: the Oocyte Mosaicism Selection model, Reproduction, vol.139, issue.1, p.19755486, 2010.

M. A. Hultén, On the paternal origin of trisomy 21 Down syndrome, Mol Cytogenet, vol.3, p.20178584, 2010.

M. F. Iulita and A. C. Cuello, Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome, Trends Pharmacol Sci, vol.35, issue.7, p.24962069, 2014.

K. T. Jones, Meiosis in oocytes: predisposition to aneuploidy and its increased incidence with age, Hum Reprod Update, vol.14, issue.2, p.18084010, 2008.

P. Kahlem, Gene-dosage effect on chromosome 21 transcriptome in trisomy 21: implication in Down syndrome cognitive disorders, Behav Genet, vol.36, issue.3, p.16557362, 2006.

I. Kola and P. J. Hertzog, Down syndrome and mouse models, Curr Opin Genet Dev, vol.8, issue.3, p.9690992, 1998.

N. V. Kovaleva, Germ-line transmission of trisomy 21: Data from 80 families suggest an implication of grandmaternal age and a high frequency of female-specific trisomy rescue, Mol Cytogenet, vol.3, p.20298592, 2010.

D. E. Kuhn, Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains, J Biol Chem, vol.285, issue.2, pp.1529-1572, 2010.

H. Kurahashi, M. Tsutsumi, S. Nishiyama, H. Kogo, H. Inagaki et al., Molecular basis of maternal age-related increase in oocyte aneuploidy, Congenit Anom (Kyoto), vol.52, issue.1, p.22348779, 2012.

N. E. Lamb, K. Yu, J. Shaffer, E. Feingold, and S. L. Sherman, Association between maternal age and meiotic recombination for trisomy 21, Am J Hum Genet, vol.76, issue.1, p.15551222, 2005.

G. M. Lambert-messerlian, H. Pinar, E. Laprade, U. Tantravahi, A. Schneyer et al., Inhibins and activins in human fetal abnormalities, Mol Cell Endocrinol, vol.225, issue.1-2, p.15451574, 2004.

E. Lana-elola, S. D. Watson-scales, E. M. Fisher, and V. L. Tybulewicz, Down syndrome: searching for the genetic culprits, Dis Model Mech, vol.4, issue.5, p.21878459, 2011.

S. E. Latchney, T. C. Jaramillo, P. D. Rivera, A. J. Eisch, and C. M. Powell, Chronic P7C3 treatment restores hippocampal neurogenesis in the Ts65Dn mouse model of Down Syndrome, 2015.

, Neurosci Lett, vol.591, p.25668489

H. C. Lee, K. L. Tan, P. S. Cheah, and K. H. Ling, Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain, Neural Plast, vol.PMID, p.26881131, 2016.

A. F. Lewanda, Preoperative evaluation and comprehensive risk assessment for children with Down syndrome, Paediatr Anaesth, vol.26, issue.4, p.26749540, 2016.

Y. Liu and W. Deng, Reverse engineering human neurodegenerative disease using pluripotent stem cell technology, Brain Res. 1638(Pt A, vol.PMID, p.26423934, 2016.

I. T. Lott and E. Head, Down syndrome and Alzheimer's disease: a link between development and aging, Ment Retard Dev Disabil Res Rev, vol.7, issue.3, p.11553933, 2001.

L. V. Lysenko, Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of Down syndrome, PLoS One, vol.9, issue.12, 2014.

N. Ma, R. F. Niu, and Y. J. Ma, Intersectin 1: a molecular linker in the central nervous system, Neurosci Bull, vol.24, issue.6, p.19037327, 2008.

A. Ma'ayan, K. Gardiner, and R. Iyengar, The cognitive phenotype of Down syndrome: insights from intracellular network analysis, NeuroRx, vol.3, issue.3, p.16815222, 2006.

A. Malassiné, J. L. Frendo, and D. Evain-brion, Trisomy 21-affected placentas highlight prerequisite factors for human trophoblast fusion and differentiation, Int J Dev Biol, vol.54, issue.2-3, pp.475-82, 2010.

R. H. Martin, Meiotic errors in human oogenesis and spermatogenesis, Reprod Biomed Online, vol.16, issue.4, p.18413061, 2008.
DOI : 10.1016/s1472-6483(10)60459-2

R. C. Mccoy, Evidence of Selection against Complex Mitotic-Origin Aneuploidy during Preimplantation Development, PLoS Genet, vol.11, issue.10, 2015.

. Mentis, Epigenomic engineering for Down syndrome, Neurosci Biobehav Rev, vol.71, pp.323-330, 2016.
DOI : 10.1016/j.neubiorev.2016.09.012

L. Migliore, F. Migheli, and F. Coppedè, Susceptibility to aneuploidy in young mothers of Down syndrome children, ScientificWorldJournal, vol.9, 2009.

S. W. Moore, Down syndrome and the enteric nervous system, Pediatr Surg Int, vol.24, issue.8, p.18633623, 2008.
DOI : 10.1007/s00383-008-2188-7

F. Mouton-liger, Developmental molecular and functional cerebellar alterations induced by PCP4/PEP19 overexpression: implications for Down syndrome, Neurobiol Dis, vol.63, p.24291518, 2014.
DOI : 10.1016/j.nbd.2013.11.016

URL : https://hal.archives-ouvertes.fr/hal-01179506

J. Muchová, I. ?it?anová, and Z. ?ura?ková, Do antioxidants play a role in therapy?, Physiol Res, vol.63, issue.5, p.24908086, 2014.

E. Nafziger and J. Vilensky, The anatomy of nuchal translucency at 10-14 weeks gestation in fetuses with trisomy 21: An incredible medical mystery, Clin Anat, vol.27, issue.3, p.24488865, 2014.

J. Ortiz-abalia, Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome, Am J Hum Genet, vol.83, issue.4, p.18940310, 2008.

P. Papavassiliou, C. Charalsawadi, K. Rafferty, and C. Jackson-cook, Mosaicism for trisomy 21: a review, Am J Med Genet A, vol.167, issue.1, p.25412855, 2015.
DOI : 10.1002/ajmg.a.36861

J. Park and K. C. Chung, New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome, Exp Neurobiol, vol.22, issue.4, p.24465139, 2013.

D. Patterson, Genetic mechanisms involved in the phenotype of Down syndrome, Ment Retard Dev Disabil Res Rev, vol.13, issue.3, p.17910086, 2007.

M. B. Petersen and M. Mikkelsen, Nondisjunction in trisomy 21: origin and mechanisms, Cytogenet Cell Genet, vol.91, issue.1-4, p.11173856, 2000.
DOI : 10.1159/000056844

G. Pidoux, Review: Human trophoblast fusion and differentiation: lessons from trisomy 21 placenta, Placenta, vol.33, p.22138060, 2012.
DOI : 10.1016/j.placenta.2011.11.007

M. Rachidi and C. Lopes, Mental retardation in Down syndrome: from gene dosage imbalance to molecular and cellular mechanisms, Neurosci Res, vol.59, issue.4, p.17897742, 2007.
DOI : 10.1016/j.neures.2007.08.007

P. L. Roubertoux and M. Carlier, Mouse models of cognitive disabilities in trisomy 21 (Down syndrome), Am J Med Genet C Semin Med Genet, vol.154, issue.4, p.20981769, 2010.
DOI : 10.1002/ajmg.c.30280

URL : https://hal.archives-ouvertes.fr/hal-00550504

A. Salehi, M. Faizi, P. V. Belichenko, and W. C. Mobley, Using mouse models to explore genotypephenotype relationship in Down syndrome, Ment Retard Dev Disabil Res Rev, vol.13, issue.3, p.17910089, 2007.
DOI : 10.1002/mrdd.20164

A. Salehi, Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome, Sci Transl Med, vol.1, issue.7, p.20368182, 2009.

P. Schneider, Identification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1, Nat Commun, vol.6, p.26310823, 2015.

L. Seewald, J. W. Taub, K. W. Maloney, and E. R. Mccabe, Acute leukemias in children with Down syndrome, Mol Genet Metab, vol.107, issue.1-2, p.22867885, 2012.

Z. Sérégaza, P. L. Roubertoux, M. Jamon, and B. Soumireu-mourat, Mouse models of cognitive disorders in trisomy 21: a review, Behav Genet, vol.36, issue.3, p.16523244, 2006.

S. L. Sherman, S. B. Freeman, E. G. Allen, and N. E. Lamb, Risk factors for nondisjunction of trisomy 21, Cytogenet Genome Res, vol.111, issue.3-4, p.16192705, 2005.

D. Sola and S. , A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials, Front Psychol, vol.6, p.26089807, 2015.

B. Souchet, Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models, Front Behav Neurosci, vol.9, p.26539088, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01263753

F. Stagni, A. Giacomini, S. Guidi, E. Ciani, and R. Bartesaghi, Timing of therapies for Down syndrome: the sooner, the better, Front Behav Neurosci, vol.9, p.26500515, 2015.

J. F. Staropoli, Tumorigenesis and neurodegeneration: two sides of the same coin?, Bioessays, vol.30, issue.8, p.18623069, 2008.

C. Turleau and M. Vekemans, Trisomie 21 : 50 ans entre me?decine et science, Med Sci (Paris), vol.26, issue.3, p.20346276, 2010.

A. Verloes, Proble?mes pose?s par les maladies ge?ne?tiques, 3e partie-A? propos d'une maladie chromosomique : la trisomie 21, Rev Prat, vol.54, issue.12, p.15461058, 2004.

D. M. Wilcock and W. S. Griffin, Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis, J Neuroinflammation, vol.10, p.23866266, 2013.

F. K. Wiseman, K. A. Alford, V. L. Tybulewicz, and E. M. Fisher, Down syndrome-recent progress and future prospects, Hum Mol Genet, vol.18, issue.R1, p.19297404, 2009.

W. B. Zigman, Atypical aging in Down syndrome, Dev Disabil Res Rev, vol.18, issue.1, pp.51-67, 2013.